NCT01822522: Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

NCT01822522
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have known HIV infection
Exclusions: Patients with active brain metastases or epidural disease that are symptomatic and/or require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT01822522

Comments are closed.

Up ↑